Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC2 | O75106 | 7/20 | 0.62 |
| ▸ | MAOA | P21397 | 2/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23370132 | 0.82 | AOC2 (0.54) | AOC2MAOAHRH3P2RX7CA2 | |
| SCHEMBL23370237 | 0.79 | AOC2 (0.64) | AOC2MAOAKMT2AALDH1A1P2RX7 | |
| SCHEMBL23358558 | 0.77 | AOC2 (1.00) | AOC2MAOAMAOB | |
| SCHEMBL23358561 | 0.77 | AOC2 (1.00) | AOC2MAOAMAOB | |
| SCHEMBL23370125 | 0.76 | AOC2 (0.60) | AOC2MAOAKMT2AALDH1A1CA2 | |
| SCHEMBL23370135 | 0.73 | AOC2 (0.75) | AOC2MAOAMAOB | |
| SCHEMBL23370120 | 0.72 | AOC2 (0.55) | AOC2KMT2AALDH1A1HTTCA2 | |
| SCHEMBL13472124 | 0.70 | P2RX7 (0.48) | AOC2MAOAHRH3RIPK1KMT2A | |
| SCHEMBL18702191 | 0.69 | P2RX7 (0.49) | AOC2MAOAHRH3RIPK1KMT2A | |
| SCHEMBL23370216 | 0.66 | AOC2 (0.66) | AOC2MAOAKMT2AELANEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026801-A1 | SSAO INHIBITORS AND USE THEREOF | ECCOGENE INC. | 2023-01-26 | — | — | US | disclosed |
| US-20210147360-A1 | SSAO INHIBITORS AND USE THEREOF | ECCOGENE INC. | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026801-A1 | SSAO INHIBITORS AND USE THEREOF | SSB, HAO1, SORD | AOC2 39/4885MAOA 17/4885HRH3 2749/4885 |
| US-20210147360-A1 | SSAO INHIBITORS AND USE THEREOF | SSB, HAO1, SORD | AOC2 39/4885MAOA 17/4885HRH3 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.